Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer L Harris

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Bioorganic & Medicinal Chemistry Letters|August 1, 2006
Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethersDavid C Tully, Hong Liu, Arnab K Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2016
Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against NeuroblastomaAndrew C Wood, Kateryna Krytska, Hannah T Ryles, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Screening the mammalian extracellular proteome for regulators of embryonic human stem cell pluripotencyRodolfo Gonzalez, Lori L Jennings, Mark Knuth, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974Jun Liu, Shifeng Pan, Mindy H Hsieh, et al.
Journal of Medicinal Chemistry|June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsThomas H Marsilje, Wei Pei, Bei Chen, et al.
Nature|November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen, Jesse S Boehm, So Young Kim, et al.
Nature|March 31, 2012
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityJordi Barretina, Giordano Caponigro, Nicolas Stransky, et al.
Nature|December 19, 2018
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityJordi Barretina, Giordano Caponigro, Nicolas Stransky, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Bioorganic & Medicinal Chemistry Letters|August 1, 2006
Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethersDavid C Tully, Hong Liu, Arnab K Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2016
Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against NeuroblastomaAndrew C Wood, Kateryna Krytska, Hannah T Ryles, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Screening the mammalian extracellular proteome for regulators of embryonic human stem cell pluripotencyRodolfo Gonzalez, Lori L Jennings, Mark Knuth, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974Jun Liu, Shifeng Pan, Mindy H Hsieh, et al.
Journal of Medicinal Chemistry|June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsThomas H Marsilje, Wei Pei, Bei Chen, et al.
Nature|November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen, Jesse S Boehm, So Young Kim, et al.
Nature|March 31, 2012
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityJordi Barretina, Giordano Caponigro, Nicolas Stransky, et al.
Nature|December 19, 2018
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityJordi Barretina, Giordano Caponigro, Nicolas Stransky, et al.
Pageof 15